完全または部分奏効を達成した中枢神経系リンパ腫患者の治療におけるオビヌツズマブの維持療法
原発性中枢神経系リンパ腫の完全奏効者または部分奏効者に対する維持療法オビヌツズマブ
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
調査の概要
詳細な説明
PRIMARY OBJECTIVE:
I. To determine the effect of maintenance obinutuzumab on duration of response (partial response [PR] or complete response [CR]) in patients with CD20+ B-cell primary central nervous system lymphoma (PCNSL) who attain PR or CR to first-line treatment with high-dose methotrexate-based chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate overall survival after PR or CR (overall survival [OS]-PRCR). II. To evaluate neurocognitive function, quality of life, and neuroimaging as indicators of neurotoxicity.
III. Progression-free survival (PFS) and overall survival (OS) will be calculated.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (MAINTENANCE THERAPY): Patients receive obinutuzumab intravenously (IV) on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.
ARM II (OBSERVATION): Patients undergo observation for a total of 2 years.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Tiffany Gervasi-Follmar
- 電話番号:503-216-1023
- メール:tiffany.gervasi-follmar@providence.org
研究連絡先のバックアップ
- 名前:Holly Marino
- 電話番号:503-216-1034
- メール:holly.marino@providence.org
研究場所
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center
-
コンタクト:
- Lindey Myers
- 電話番号:917-453-2968
- メール:myersl1@mskcc.org
-
主任研究者:
- Christian Grommes, MD
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- 引きこもった
- Cleveland Clinic
-
-
Oregon
-
Portland、Oregon、アメリカ、97225
- 募集
- Providence Health & Services; Providence Neurological Specialties
-
主任研究者:
- Prakash Ambady, MD
-
コンタクト:
- Kai Darke
- 電話番号:503-216-0627
- メール:kai.darke@providence.org
-
コンタクト:
- Kimberly Perry
- 電話番号:971-231-8245
- メール:kimberly.perry2@providence.org
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- 募集
- Pennsylvania State University
-
主任研究者:
- Dawit Aregawi, MD
-
コンタクト:
- Micaiah Grien
- 電話番号:283063 717-531-0003
- メール:mgrien@pennstatehealth.psu.edu
-
コンタクト:
- Sara Craig
- 電話番号:285799 717-531-0003
- メール:scraig2@pennstatehealth.psu.edu
-
-
Vermont
-
Burlington、Vermont、アメリカ、05405
- 募集
- University of Vermont
-
コンタクト:
- Isza Parchini
- 電話番号:802-656-9447
- メール:isza.parchini@uvahealth.org
-
コンタクト:
- George Davis
- メール:george.davis@uvmhealth.org
-
主任研究者:
- Alissa Thomas, MD
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- 募集
- University of Virginia
-
主任研究者:
- David Schiff, MD
-
コンタクト:
- Nija Desai
- 電話番号:434-982-6455
- メール:NND2A@uvahealth.org
-
コンタクト:
- Patrick Heffernan
- 電話番号:434-243-9508
- メール:YWW2NJ@uvahealth.org
-
-
Washington
-
Seattle、Washington、アメリカ、98122
- 募集
- Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute
-
コンタクト:
- Nathan Hansen
- 電話番号:206-320-3542
- メール:nathan.hansen@swedish.org
-
コンタクト:
- Gary Brown
- 電話番号:206-320-2608
- メール:gary.brown@swedish.org
-
主任研究者:
- Alipi Bomn, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- CD20+ B-cell primary central nervous system lymphoma (PCNSL) confirmed at the time of diagnosis by histology, cytology, or immunocytochemistry from cerebrospinal fluid (CSF); diagnosis must be documented by pathology report.
- Must have undergone first-line treatment with a high-dose methotrexate-based chemotherapy regimen with or without brain radiotherapy; high-dose methotrexate is defined as >= 3 grams/m^2; methotrexate dose reduction for creatinine clearance < 100 ml/min is permitted
- Must be within 75 days of completion of first-line treatment regimen at the time of randomization; must have achieved objective response (PR or CR/unconfirmed complete response [CRu]) to first-line treatment
- Brain magnetic resonance imaging (MRI) documenting objective response must be obtained within 30 days before randomization
- If CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or a slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; Note: CR requires complete disappearance of all enhancing abnormalities on gadolinium-enhanced MRI; if CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; for CRu, some patients will have a small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; it is often difficult to ascertain whether this represents a residual nidus of tumor or scar tissue; if the abnormality does not change or slowly involutes without therapy and corticosteroids, it is reasonable to categorize as a CRu; at the time CR/CRu is determined, the patient should not have used corticosteroids for at least two weeks
- Karnofsky performance status (KPS) >= 60; Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
- Signed informed consent form (ICF)
- Ability and willingness to comply with the requirements of the study protocol
- Total bilirubin < 3 x the upper limit of normal (ULN), ≤ 7 days before date of randomization
- Creatinine clearance > 30 mL/min (calculated according to institutional standards or using Cockcroft-Gault formula), ≤ 7 days before date of randomization
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 5 x ULN, ≤7 days before date of randomization
- Platelet ≤ 75,000 cells/mm^3, ≤ 7 days before date of randomization
- Hemoglobin > 9 g/dL, ≤ 7 days before date of randomization
- Absolute neutrophil count > 1.5 x 10^3 cells/mm^3, ≤ 7 days before date of randomization
- Surgically sterile or agree to use effective contraception using an adequate measure of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly while receiving obinutuzumab and >= 18 months after the last dose of obinutuzumab for women, and 180 days after the last dose of obinutuzumab for men
Exclusion Criteria:
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin lymphoma
- Known hypersensitivity to any of the study drugs
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible; patients with a malignancy that has been treated, but not with curative intent, will also be excluded, unless the malignancy has been in remission without treatment for >= 2 years prior to randomization
- Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks prior to study randomization
- Major surgery within 4 weeks prior to study randomization
- Known infection with human immunodeficiency virus (HIV)
- Positive hepatitis serologies:
- Hepatitis B (HBV): patients with positive serology for hepatitis B defined as positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); patients who are positive for anti-HBc may be considered for inclusion in the study on a case-by-case basis if they are hepatitis B viral deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA testing by real-time polymerase chain reaction (PCR); patients with positive serology may be referred to a hepatologist or gastroenterologist for appropriate monitoring and management
- Hepatitis C (HCV): patients with positive hepatitis C serology unless HCV ribonucleic acid (RNA) is confirmed negative and may be considered for inclusion in the study on a case-by-case basis
- Women who are pregnant or lactating
- Vaccination with a live vaccine a minimum of 4 weeks prior to study randomization
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I (obinutuzumab
Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry. Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry. |
|
アクティブコンパレータ:Arm II (observation)
Patients undergo observation for a total of 2 years. |
Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry. Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Partial response (PR) or complete response (CR) duration
時間枠:From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years
|
PR or CR duration will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios. |
From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall survival (OS) after CR
時間枠:From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years
|
OS after PR or CR will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios. |
From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years
|
|
Neurocognitive function - Wechsler Adult Intelligence Scale
時間枠:Up to 2 years
|
Will be measured by the Wechsler Adult Intelligence Scale. Scale range 0 to 16 Forward; 0 to 14 Backward. Higher the score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20-item
時間枠:Up to 2 years
|
Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module-20 (EORTC QLQ-BN20) questionnaire. Scale 20 to 80 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Progression free survival (PFS)
時間枠:From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years
|
PFS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years
|
|
Overall survival
時間枠:From the start date of first-line PCNSL treatment to death, assessed up to 2 years.
|
OS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
From the start date of first-line PCNSL treatment to death, assessed up to 2 years.
|
|
Neurocognitive function - Hopkins Verbal Learning Test-Revised
時間枠:Up to 2 years
|
Will be measured by the Hopkins Verbal Learning Test-Revised. Test evaluates total recall, delayed recall, percent of retention, and recognition. Higher score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Grooved Pegboard Test
時間枠:Up to 2 years
|
Will be measured by the Grooved Pegboard Test. Scale 0 seconds to time of completion in minutes and seconds. Higher time to completion means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Trail Making Test
時間枠:Up to 2 years
|
Will be measured by the Trail Making Test. Scale Part A: 0 seconds to 100 seconds (time of greater than 100 seconds discontinues the test. Scale Part B: 0 seconds to 300 seconds (time of greater than 300 seconds discontinues the test. Number of errors recorded. Higher time to completion and greater number of errors means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Brief Test of Attention
時間枠:Up to 2 years
|
Will be measured by the Trail Making Test. Scale 0 to 20 points. Higher score mean better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item
時間枠:Up to 2 years
|
Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Core 30-item (EORTC QLQ-C30) questionnaire. Scale 30 to 126 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
協力者と研究者
捜査官
- 主任研究者:Prakash Ambady, MD、Providence Health & Services
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- PHS-OB-PCNSL-01
- ML29496 (その他の識別子:Genentech, Inc.)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。